Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Reduce” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received an average rating of “Reduce” from the twelve ratings firms that are currently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.20.

FULC has been the subject of several recent analyst reports. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Piper Sandler downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd. Citigroup lowered Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Finally, HC Wainwright lowered Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research report on Tuesday, June 2nd.

Insider Activity

In related news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at approximately $39,883.55. The trade was a 62.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC increased its stake in Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after purchasing an additional 346,136 shares during the last quarter. Braidwell LP acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $2,019,000. Catalio Capital Management LP bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at about $2,277,000. Aberdeen Group plc grew its position in shares of Fulcrum Therapeutics by 809.0% during the 4th quarter. Aberdeen Group plc now owns 1,254,027 shares of the company’s stock valued at $14,183,000 after buying an additional 1,116,066 shares during the last quarter. Finally, Nicholas Investment Partners LP acquired a new stake in Fulcrum Therapeutics during the fourth quarter worth about $2,069,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $3.65 on Monday. The firm has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $7.39. The company has a market capitalization of $243.20 million, a PE ratio of -3.17 and a beta of 3.01. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. Equities research analysts predict that Fulcrum Therapeutics will post -0.67 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.